Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
- Conditions
- Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT02334865
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
HER2-Peptide Vaccination of Patients With Solid Tumors
- Conditions
- Breast CancerGastric Cancer
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 2
- Registration Number
- NCT02276300
- Locations
- 🇩🇪
III.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM, Munic, Bavaria, Germany
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
- Conditions
- Smoldering Multiple Myeloma (sMM)Acute Myelogenous Leukemia (AML)Multiple Myeloma (MM)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Benovus Bio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02240537
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
Leukine (Sargramostim) for Parkinson's Disease
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 37
- Registration Number
- NCT01882010
- Locations
- 🇺🇸
Neurology Consultants of Nebraska PC, Omaha, Nebraska, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Sargramostim for Myeloid Dendritic Cell Deficiency
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 2
- Registration Number
- NCT01871467
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?
- Conditions
- Immuno-suppressionCritical IllnessSepsis
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 64
- Registration Number
- NCT01653665
- Locations
- 🇬🇧
Sunderland Royal Hospital, Sunderland, United Kingdom
🇬🇧Freeman Hospital, Newcastle upon Tyne, Tyne And Wear, United Kingdom
🇬🇧Queen Elizabeth Hospital, Gateshead, Tyne And Wear, United Kingdom
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 2
- Registration Number
- NCT01511068
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
- Conditions
- Multiple MyelomaLeukemia, Myeloid, AcuteMyelodysplastic SyndromesLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellHodgkin Disease
- Interventions
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT01158118
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Conditions
- Advanced MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Recurrent MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7Stage IIIA Cutaneous Melanoma AJCC v7Unresectable MelanomaMetastatic MelanomaStage III Cutaneous Melanoma AJCC v7
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 245
- Registration Number
- NCT01134614
- Locations
- 🇺🇸
Eureka Hospital, Eureka, Illinois, United States
🇺🇸Illinois CancerCare-Galesburg, Galesburg, Illinois, United States
🇺🇸Hinsdale Hematology Oncology Associates Incorporated, Hinsdale, Illinois, United States
Inhaled GM-CSF Therapy of Autoimmune PAP
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 18
- Registration Number
- NCT00901511
- Locations
- 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.